Skip to main content
editorial
. 2022 Jun 24;30(9):7067–7077. doi: 10.1007/s00520-022-07103-5

Fig. 1.

Fig. 1

Synopsis of international guidelines on the prophylactic use of G-CSF; additional risk factors mentioned by ASCO guidelines: advanced disease, poor performance status or poor nutritional status, cardiovascular disease multiple comorbid conditions HIV infection [23]. Secondary prophylaxis is indicated if neutropenia complications occurred without G-CSF or neutropenia-related cycle delays were necessary. Assessment is required after each cycle of chemotherapy.